Drug intelligence / Profile preview

INV-9020

Development stage: Preclinical
Lead developer: Ionova Life Sciences
Modality: Small Molecules

Overview

INV-9020 is a preclinical small molecule inhibitor targeting Signal Transducer and Activator of Transcription 6 (STAT6), developed by Ionova Life Sciences. STAT6 is a key transcription factor in the IL-4 and IL-13 signaling pathways, which are central to the pathogenesis of Type 2 (Th2) mediated inflammatory and autoimmune diseases. By inhibiting STAT6, INV-9020 aims to modulate the immune response in conditions such as atopic dermatitis, asthma, and other autoimmune disorders. The drug is currently in the preclinical stage of development.

Targets

STAT6 (Signal Transducer and Activator of Transcription 6)

Beyond the preview

Go deeper on INV-9020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INV-9020.

Explore the full profile